Review Article

Long Noncoding RNA in Preeclampsia: Transcriptional Noise or Innovative Indicators?

Xiuhua Yang and Tao Meng

Department of Obstetrics, The First Hospital of China Medical University, Shenyang, Liaoning, China

Correspondence should be addressed to Tao Meng; cmumt@163.com

Received 4 January 2019; Revised 25 March 2019; Accepted 31 March 2019; Published 14 April 2019

Academic Editor: Hai-Feng Pan

Copyright © 2019 Xiuhua Yang and Tao Meng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Preeclampsia (PE) is termed as an obstetric issue that is characterized by hypertension (≥140/90 mm Hg), together with proteinuria following 20 weeks of pregnancy [1]. The incidence of PE is 5-8%, and it may involve the liver, kidney, cardiovascular system, cerebrovascular system, and blood system [2]. Until today, PE still constitutes a severe threat to the lives of both the mothers and fetuses. Females with PE are prone to an augmented threat of developing cardiovascular illnesses in the future [3]. Besides that, it is held that the underlying causes of PE count on the inflammatory elements, in addition to the damaged endothelial function, vasoactive elements, oxidative stress, and genetic causes [4–8]. Nowadays, the “Two-phase Disorder” [9] statement of PE is quite famous. In the preliminary phase of the embryonic implantation, trophoblasts invade the uterine wall, besides helping with uterine artery remodeling. There is an increase in the diameter of blood vessels, together with the decline in the blood flow resistance, aimed at ensuring a sufficient amount of blood flow [10]. Trophoblast cells are quite pivotal for uterine spiral artery remodeling. In the patients, who have PE, the invasive potential of trophoblasts declines, causing the dysplasia of uterine spiral artery remodeling, further leading to a shallow placental implantation [11]. Nowadays, the effective treatment for PE is still regarded as the termination of pregnancy; nevertheless, it does not constitute a reasonable option in case of too few numbers of gestational weeks, coupled with an immature fetus [12]. There have been carried out several investigations primarily emphasizing the physical and biochemical indicators for the forecast, diagnosis, and management [13]. Nevertheless, no exclusive indicator could be put to use as a standard and productive indicator. Accordingly, it is quite essential to investigate the pathogenesis for the purpose of finding a means of preventing and treating PE [14].

Long noncoding RNAs (lncRNAs) regulate the gene expression at the transcriptional level and the posttranscriptional level [15]. In the past, lncRNAs were considered as the transcriptional noise. At present, there are several evidence showing that lncRNAs are associated with both the occurrence and development of numbers of illnesses, for instance, cancer [16], cardiovascular illnesses [17], and neurological illnesses [18]. Besides that, a few investigations have suggested that lncRNAs take part in numerous cell biological procedures that include cell proliferation, together
with cell migration, cell apoptosis, X-chromosome inactivation, gene imprinting, and stem cell transformation [19–22]. LncRNAs contribute by means of a number of mechanisms. They function as scaffolds, signals, and antisense decoys, in addition to participating in the transcriptional disturbance. Single IncRNA less often performs multiple functions [23]. Scaffold IncRNAs bring together proteins and other RNAs for becoming a bigger functional compound; for instance, the telomerase RNA compound was required for the telomere repeat complex [24], and the polycomb repressor complex was needed for the histone regulation [25]. The transcription of a few lncRNAs could manifest the silencing of colocated protein-coding genes [26] or function as an indicator of the upstream transcriptional element. Decoy IncRNAs could function through the combing of a target protein, impeding the protein from functioning as it requires [27] or through combing and separating of small regulatory RNAs, for instance, microRNAs (miRNAs) [28]. In comparison with messenger RNAs (mRNAs), the superiority of targeting IncRNAs indicates that it is capable of causing changes in several downstream signal pathways, accordingly carrying out various functions [29]. The demerits associated with being capable of playing a role in multiple downstream pathways are that it may give rise to several unintended damaging effects. That is why, the role of IncRNAs requires carefully understanding before they could be put to use as a therapeutic indicator. In comparison with a normal pregnancy, there were a number of differentially expressed pathways are that it may give rise to several unintended damaging effects. That is why, the role of IncRNAs requires carefully understanding before they could be put to use as a therapeutic indicator. In comparison with a normal pregnancy, there were a number of differentially expressed lncRNAs in the placentas of PE patients, which suggested that these lncRNAs might be associated with PE [30]. Besides that, several investigations have demonstrated that IncRNAs could take part in the progress of PE by impacting on the function of trophoblasts. Accordingly, the current review aims to discuss the relationship between IncRNAs and PE in recent years, besides putting efforts for the discovery of the pathogenesis of PE from a new perspective.

2. LncRNA Microarray Study in PE

Nowadays, people have discovered many IncRNAs when compared with protein-coding genes in the genome [31]. Owing to the development of the next-generation sequencing technology, increasing numbers of IncRNAs have been discovered. There was an age-matched IncRNA microarray study. The empirical group comprised 6 patients having the early-onset PE (onset before 34 weeks) and the control group was constituted by 6 patients with a premature delivery. The investigation discovered that there were 15,646 upregulated and 13,178 downregulated IncRNAs in the placenta tissues of early-onset PE patients [30]. For the purpose of exploring the underlying functions of these differentially expressed IncRNAs, GO analysis was performed, which subsequently revealed that the pathways associated with cell migration were markedly enriched [30]. Another microarray investigation highlighted 738 differently expressed IncRNAs in the placenta of PE in comparison with normal pregnancies [32]. LOC391533, LOC284100, and CEACAMP8 were confirmed to be increased in the placenta of PE, besides being discovered linked to both the lipid metabolism and angiogenesis [32]. Moreover, it was also discovered that there were 163 differentially expressed IncRNAs in late-onset PE (onset over 34 weeks) placentas in comparison with the normal placentas [33]. NONHSAT16812 and NONHSAT145880 both might be utilized as indicators for PE since they were also confirmed in plasma specimens [33].

3. LncRNA RNA Sequencing (RNA-Seq) Study in PE

RNA-Seq is a better method than microarray to discover new IncRNAs [34, 35]. Liu S. et al. found some IncRNAs associated with PE, together with discovering that the Jak-stat pathway was related to the etiology of PE [36]. Jing Tong et al. performed another RNA-seq study who collected decidual tissues from normal pregnancy (n=3), early-onset PE patients (n=3), and late-onset PE females (n=3), and the results showed that there were 32 aberrant IncRNAs between early-onset PE and normal pregnancy, 53 differentially expressed IncRNAs between late-onset PE and normal pregnancy, and 32 differentially expressed IncRNAs between early-onset PE and late-onset PE, demonstrating that the pathogenesis of early-onset PE was different from that of late-onset PE [37].

4. LncRNAs Affect Cellular Functions of Trophoblast Cells

The deficiency of uterine spiral artery remodeling is the early cause of PE. The capabilities of trophoblast migration and invasion have a close association with epithelial-mesenchymal transition (EMT), which is related to the placental development [38]. The decreased trophoblast proliferation, migration, invasion, and stimulated apoptosis constitute the pivotal reasons leading to PE [39]. LncRNAs are capable of impacting both the occurrence and development of PE through the modification of these functions of trophoblast cells. Some IncRNAs were discovered as increasing in PE (Table 1). The increased RPAIN inhibited the trophoblast invasion, together with inducing the apoptosis through regulating Cilq, accordingly promoting the aggravation of PE [40]. Moreover, increased IncRNA uc.187 in the placentas of PE patients promoted the progression of PE not just through the reduction of cell proliferation and invasion but also induced cell apoptosis [41]. The upregulation of IncRNA CCAT1 was carried out in PE, which had the ability to induce the progression of PE by decreasing the level of CDK4 [42]. There was an increase in the expression of IncRNA PRNCR1 in PE as well [43]. As discovered, the mechanism of IncRNA PRNCR1 involved the regulation of the Mitogen-activated protein kinase (MAPK) signaling pathway [43]. There was observed an increase in IncRNA DLX6-AS1 in the placentas of PE patients, leading to PE through the manipulation of the miR-376c/GADD45A expression [44]. The SPRY4-IT1 upregulation substantially decreased cell migration and proliferation, meanwhile still increasing cell apoptosis [45]. LncRNA STOX2-IT3 might decrease the differentiation and invasion of trophoblasts through the regulation of STOX2, followed...
by making a contribution towards PE [46]. LINC-HELLP was associated with the familial HELLP in Dutch [47]. LINC-HELLP was discovered to be linked to trophoblast proliferation and invasion, and LINC-HELLP mutation could attenuate the differentiation of trophoblasts [48]. LncRNA uc003fri was upexpressed in the vessels of PE placentas in comparison with the normal ones through the regulation of “HIF1-α–lncRNA uc003fri–CCL5” axis, which resulted into the development of PE [49].

In contrast, the downregulation of some lncRNAs was also confirmed in PE (Table 2). LncRNA MALAT-1 was substantially reduced in the placentas of PE patients, inducing cell proliferation, meanwhile decreasing the cell cycle and cell apoptosis [50]. In addition to that, lncRNA-ATB was manifested to be associated with the incidence of PE by means of the manipulation of the procedure of the cell invasion, coupled with the development of the endothelial vessels [51]. The decline in small nucleolar RNA host gene 5 (SNHG5) in the placentas of PE women indicated that SNHG5 induced not only cell proliferation, but also cell invasion, and migration through the manipulation of the miR-26a-5p/N-cadherin axis [52]. The expression of lncRNA maternally expressed gene 3 (MEG3) in PE placentas was decreased as well [53]. The downregulation of lncRNA MEG3 had the potential of inhibiting cell migration, inducing cell apoptosis, and increasing the expressions of NF-κB, Caspase 3, and Bax, further causing the dysplasia of uterine spiral artery [53]. LncRNA TUG1 was decreased in the placental tissues of PE women indicated that TUG1 happened to be linked to the development of PE [54]. LncRNA RP11-465J10.10 was decreased in the placenta tissues of PE patients, indicating the development of PE [55]. H9 was decreased in the early-onset severe PE through the regulation of miR-675/Nodal Modulator 1 (NOMO) axis and Nodal signal pathway, and H9 was capable of increasing cell proliferation [56]. The decreased level of EGFR Antisense RNA1 (EGFR-AS1) in PE placentas of PE women indicated that SNHG5 induced not only cell proliferation, but also cell migration and angiogenesis in trophoblast cell lines by targeting Jun-B protein [60].

Table 1: Increased lncRNAs related to cellular functions of trophoblast cells in PE.

| LncRNA name | Functions related to PE | Regulating gene/signal pathway | Reference |
|-------------|-------------------------|--------------------------------|-----------|
| RPAIN       | Inhibits invasion and promotes cell apoptosis | Clq | [40] |
| uc.187      | Inhibits cell proliferation, invasion and increases cell apoptosis | unknown | [41] |
| CCAT1       | Inhibits cell proliferation | CDK4 | [42] |
| PRNCR1      | Reduces cell viability | MAPK signaling pathway | [43] |
| DLX6-AS1    | Decreases cell proliferation, migration and invasion | miR-376c/GADD45A axis | [44] |
| SPRY4-IT1   | Decreases cell migration and proliferation, increases cell apoptosis | unknown | [45] |
| STOX2-IT3   | Decreases cell invasion | STOX2 | [46] |
| HELLP       | Reduces cell differentiation, proliferation and invasion | YBX1, PCBPI, PCBPI, RPS6 and RPL7 | [47, 48] |
| uc003fri    | Reduces cell proliferation and migration | HIF1-α–lncRNA uc003fri–CCL5 | [49] |
| CEACAMP8    | unknown | unknown | [32] |
| LOC391533   | unknown | unknown | [32] |
| LOC284100   | unknown | unknown | [32] |

MAPK, Mitogen-activated protein kinase.

The expression level of dendritic cells (DCs) for the production of T regulatory (Treg) cells in PE patients substantially declined [61]. Lnc-DC just appeared in PE (Table 2). LncRNA MALAT-1 was substantially reduced in the placentas of PE patients, inducing cell proliferation, meanwhile decreasing the cell cycle and cell apoptosis [50]. In addition to that, lncRNA-ATB was manifested to be associated with the incidence of PE by means of the manipulation of the procedure of the cell invasion, coupled with the development of the endothelial vessels [51]. The decline in small nucleolar RNA host gene 5 (SNHG5) in the placentas of PE women indicated that SNHG5 induced not only cell proliferation, but also cell invasion, and migration through the manipulation of the miR-26a-5p/N-cadherin axis [52]. The expression of lncRNA maternally expressed gene 3 (MEG3) in PE placentas was decreased as well [53]. The downregulation of lncRNA MEG3 had the potential of inhibiting cell migration, inducing cell apoptosis, and increasing the expressions of NF-κB, Caspase 3, and Bax, further causing the dysplasia of uterine spiral artery [53]. LncRNA TUG1 was decreased in the placental tissues of PE patients, indicating the development of PE [54]. LncRNA RP11-465J10.10 was decreased in the placenta tissues of PE patients in early-onset PE by targeting MMP9 [30]. In addition, functional investigations revealed that HOXA11-AS was capable of increasing Ezh2 and lysine-specific demethylase 1 (LSD1) and regulating RND3 level in the nucleus, while in the cytoplasm, HOXA11-AS regulated the HOXA7 level via sponged miR-15b-5p, which changed cell proliferation [55]. H9 was decreased in the early-onset severe PE through the regulation of miR-675/Nodal Modulator 1 (NOMO) axis and Nodal signal pathway, and H9 was capable of increasing cell proliferation [56]. The decreased level of EGFR Antisense RNA1 (EGFR-AS1) in PE placentas of PE women indicated that SNHG5 induced not only cell proliferation, but also cell migration and angiogenesis in trophoblast cell lines by targeting Jun-B protein [60].

5. LncRNAs Affect Immune Response in PE

The expression level of dendritic cells (DCs) for the production of T regulatory (Treg) cells in PE patients substantially declined [61]. Lnc-DC just appeared in DCs, and functional experiments have indicated that the downregulation of lnc-DC damaged the differentiation of monocytes into DCs, accordingly performing the attenuation of the production of Treg cells by DCs. Lnc-DC could increase the phosphorylation of tyrosine-705 in the cytoplasm, followed by impacting the transcription of downstream genes and stimulating the differentiation as well as the development of DCs [62]. In addition, lnc-DCs stimulated the development of decidual DCs in PE females, besides contributing to a rise in Th1 cells, leading to the etiology of PE [63]. MALAT1-upregulated mesenchymal


Table 2: Decreased lncRNAs related to cellular functions of trophoblast cells in PE.

| LncRNA name      | Functions related to PE                                      | Regulating gene/signal pathway                  | Reference |
|------------------|-------------------------------------------------------------|-------------------------------------------------|-----------|
| MALAT-1          | Increases proliferation, decreases apoptosis               | unknown                                         | [50]      |
| ATB              | Increases migration, proliferation, tube-formation of HTR-8/SVneo cells | unknown                                         | [51]      |
| SNHG5            | Promotes cell proliferation, invasion and migration         | miR-26a-5p/N-cadherin axis                      | [52]      |
| MEG3             | Reduces apoptosis and promotes migration                     | unknown                                         | [53]      |
| TUG1             | Increases proliferation, migration, and invasion and reduces apoptosis | Ezh2, RND3                                      | [54]      |
| RP11-465L10.10   | Increases cell migration and motility                       | MMP9                                            | [30]      |
| HOXAI1-AS        | Increases cell proliferation and migration                  | Ezh2, Lsd1, RND3miR-15b-5p/HOXA7 axis           | [55]      |
| H19              | Increases cell proliferation                                 | miR-675/NOMO1 Nodal signaling                   | [56]      |
| EGFR-AS1         | Increases cell proliferation                                 | JAK/STAT signaling pathway                      | [57]      |
| linc00473        | Increases cell proliferation and reduces cell apoptosis     | TFP12, Lsd1                                    | [58]      |
| PVT1             | Increases cell proliferation and reduces cell apoptosis     | ANGPTL4, EZH2                                  | [59]      |
| MVIH             | Promotes cell growth, migration, invasion and angiogenesis | Jun-B                                           | [60]      |

SNHG5, small nuclear RNA host gene 5; MEG3, maternally expressed gene 3; NOMO1, Nodal Modulator 1; EGFR-AS1, EGFR Antisense RNA1; TFP12, tissue factor pathway inhibitor 2; Lsd1, lysine-specific demethylase 1; ANGPTL4, angiopoietin-like 4.

Figure 1: The biological functions of lncRNAs in PE. LncRNAs can exert an impact on both the occurrence and development of PE through the changes in the biological functions of trophoblasts (including cell proliferation, migration, invasion, and apoptosis), immune regulation, epigenetic regulation, decidualization, and energy metabolism, and impaired glycolysis may lead to the decreased decidualization.

6. LncRNAs Affect PE by Epigenetic Regulation

LncRNAs had the potential of mediating the gene expression at the epigenetic level [65]. Moreover, the alternative epigenetic mediation of the H19-IGF2 domain in placental tissues was associated with PE, resulting into placental dysplasia in the early pregnancy [66]. LncRNA H19 rs217727 polymorphism was related to a higher chance of having PE [67]. Moreover, not only the CTC, but also TTC and TTT haplotypes had an association with the PE susceptibility [67]. STOX2-IT3-lncRNA performs the role of a permissive cis-acting regulatory factor of STOX2 selective splicing [46].

7. LncRNAs Affect Decidualization and Energy Metabolism in PE

There have been numerous investigations suggesting that PE has an association with the dysplasia of decidualization [68]. Moreover, the poor decidualization can make a contribution...
to the decreased invasive potential of extravillous trophoblasts, dysplasia of the uterine spiral artery, and decreasing the blood flow at the maternal-fetal interface [69]. Placental ischemia results into the increased expression of toxic cytokines in the maternal peripheral blood, further impairing endothelial cells. Glycolysis is considered as quite pivotal for the development of endothelial cells, and decreased glycolysis was capable of contributing to the impaired decidualization [70]. The decreased level of HK2P1 and HK2 might be associated with the occurrence as well as the development of PE by means of the impairment of glycolysis and decidualization [71]. HK2P1 mediated the expression of HK2 by functioning as a competing endogenous RNA (ceRNA) [71]. These findings put forward innovative ideas regarding the etiology of PE, and the new regulating axis, which suggested HK2P1, HK2, and miR-6887-3p, might be put to use as the innovative indicators for PE [71]. Both HK2P1, HK2, and miR-6887-3p might be put to use as the innovative indicators for PE [71]. Both PGK1 and PGK1P2 constitute a couple of ceRNAs related to the decreased level of HK2P1, HK2, and miR-6887-3p, in addition to being quite important in the mechanism of decidualization by means of the mediation of the angiogenesis and glycolysis [72]. Decreased expressions of HK2 by functioning as a ceRNA mediate the expression of HK2P1 in the decidual tissues might give rise to the impaired decidualization and the occurrence of PE [72]. At present, increasing numbers of investigations have suggested that the occurrence of PE is associated with the abnormal energy metabolism. The expression of IncZBTB39-1:2 in placenta has the potential of decreasing the trophoblast activity by means of impacting the energy regulation, which may promote the progress of PE [73].

8. Conclusion

In the current review, we have discussed about the latest research progress of IncRNAs and PE. According to the retrieved data, we concluded that IncRNAs can exert an impact on both the occurrence and development of PE through the changes in the biological functions of trophoblasts, immune regulation, epigenetic regulation, decidualization, and energy metabolism (Figure 1). Even though the functions of many IncRNAs are not clear, the mechanisms of IncRNAs in PE will help us to better understand the pathogenesis of PE and help us to find targets for predicting and diagnosing PE in the future.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] B. Jim and S. A. Karumanchi, “Preeclampsia: pathogenesis, prevention, and long-term complications,” Seminars in Nephrology, vol. 37, no. 4, pp. 386–397, 2017.
[2] L. Duley, “The global impact of pre-eclampsia and eclampsia,” Seminars in Perinatology, vol. 33, no. 3, pp. 130–137, 2009.
[3] R. Ahmed, J. Dunford, R. Mehran et al., “Pre-eclampsia and future cardiovascular risk among women: a review,” Journal of the American College of Cardiology, vol. 63, no. 18, pp. 1815–1822, 2014.
[4] A. F. Saftlas, H. Beydoun, and E. Triche, “Immunogenetic determinants of preeclampsia and related pregnancy disorders: a systematic review,” Obstetrics & Gynecology, vol. 106, no. 1, pp. 162–172, 2005.
[5] J. P. Granger, B. T. Alexander, M. T. Llinas, W. A. Bennett, and R. A. Khalil, “Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction,” Hypertension, vol. 38, no. 3, pp. 718–722, 2001.
[6] S. Rana, S. A. Karumanchi, R. J. Levine et al., “Sequential changes in angiogenic factors in early pregnancy and risk of developing preeclampsia,” Hypertension, vol. 50, no. 1, pp. 137–142, 2007.
[7] M. Noris, M. Todeschini, P. Cassis et al., “L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species,” Hypertension, vol. 43, no. 3, pp. 614–622, 2004.
[8] J. L. Bartha, R. Romero-Carmona, R. Torrejon-Cardoso, and R. Comino-Delgado, “Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension,” American Journal of Obstetrics & Gynecology, vol. 187, no. 3, pp. 735–740, 2002.
[9] NC. Ngene and J. Moodley, “Role of angiogenic factors in the pathogenesis and management of pre-eclampsia,” International Journal of Gynecology & Obstetrics, vol. 141, no. 1, pp. 5–13, 2002.
[10] J. R. Duncan, A. M. Tobiasz, Z. Bursac, E. V. Rios-Doria, M. H. Schenone, and G. Mari, “Uterine artery flow velocity waveforms before and after delivery in hypertensive disorders of pregnancy near term,” Hypertension in Pregnancy, vol. 37, no. 3, pp. 131–136, 2018.
[11] F. Louwen, C. Muschol-Steinmetz, J. Reinhard, A. Reitter, and J. Yuan, “A lesson for cancer research: Placental microarray gene analysis in preeclampsia,” Oncotarget, vol. 3, no. 8, pp. 759–773, 2012.
[12] E. Esteve-Valverde, R. Ferrer-Oliveras, N. Gil-Alberas, A. Baraldè-Farrè, E. Llurba, and J. Alijotas-Reig, “Pravastatin for preventing and treating preeclampsia: a systematic review,” Obstetrical & Gynecological Survey, vol. 73, no. 1, pp. 40–55, 2018.
[13] H. Park, S. Shim, D. Cha et al., “Combined screening for early detection of pre-eclampsia,” International Journal of Molecular Sciences, vol. 16, no. 8, pp. 17952–17974, 2015.
[14] J. A. Bastek and M. A. Elovitz, “The role and challenges of biomarkers in spontaneous preterm birth and preeclampsia,” Fertility and Sterility, vol. 99, no. 4, pp. 1117–1123, 2013.
[15] C. M. Klinge, “Non-coding RNAs: Long non-coding RNAs and microRNAs in endocrine-related cancers,” Endocrine-Related Cancer, vol. 25, no. 4, pp. R259–R282, 2018.
[16] J. Wang, X. Liu, H. Wu et al., “CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer,” Nucleic Acids Research, vol. 38, no. 16, pp. 5366–5383, 2010.
[17] A. Leung, C. Trac, W. Jin et al., “Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells,” Circulation Research, vol. 113, no. 3, pp. 266–278, 2013.
[18] R. Johnson, “Long non-coding RNAs in Huntington’s disease neurodegeneration,” Neurobiology of Disease, vol. 46, no. 2, pp. 245–254, 2012.
[19] M. Eißmann, T. Gutschner, M. Hämmerle et al., “Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development,” RNA Biology, vol. 9, no. 8, pp. 1076–1087, 2012.
C. J. Brown, B. D. Hendrich, J. L. Rupert et al., “The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus,” Cell, vol. 71, no. 3, pp. 527–542, 1992.

M. V. Koerner, F. M. Pauer, R. Huang, and D. P. Barlow, “The function of non-coding RNAs in genomic imprinting,” Development, vol. 136, no. 11, pp. 1771–1783, 2009.

K. Kim, J. Jutooru, G. Chadalapaka et al., “HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer,” Oncogene, vol. 32, no. 13, pp. 1616–1625, 2013.

S. Geisler and J. Coller, “RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts,” Nature Reviews Molecular Cell Biology, vol. 14, no. 11, pp. 699–712, 2013.

K. Collins, “Physiological assembly and activity of human telomerase complexes,” Mechanisms of Ageing and Development, vol. 129, no. 1-2, pp. 91–98, 2008.

J. L. Rinn, M. Kertesz, J. K. Wang et al., “Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs,” Cell, vol. 129, no. 7, pp. 1311–1323, 2007.

F. Mohammad, T. Mondal, and C. Kanduri, “Epigenetics of imprinted long noncoding RNAs,” Epigenetics, vol. 4, no. 5, pp. 277–286, 2009.

T. Hung, Y. Wang, M. F. Lin et al., “Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters,” Nature Genetics, vol. 43, no. 7, pp. 621–629, 2011.

A. Bayoumi, A. Sayed, Z. Broskova et al., “Crosstalk between long noncoding RNAs and MicroRNAs in health and disease,” International Journal of Molecular Sciences, vol. 17, no. 3, p. 356, 2016.

I. Balgkouranidou, D. Matthias, A. Karayiannakis et al., “Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients,” Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, vol. 778, pp. 46–51, 2015.

W. Long, C. Rui, X. Song et al., “Distinct expression profiles of lncRNAs between early-onset preeclampsia and preterm controls,” Clinica Chimica Acta, vol. 463, pp. 193–199, 2016.

S. Djebali, C. A. Davis, and A. Merkel, “Landscape of transcription in human cells,” Nature, vol. 489, no. 7414, pp. 101–108, 2012.

X. He, Y. He, B. Xi et al., “LncRNAs expression in preeclampsia placenta reveals the potential role of LncRNAs contributing to preeclampsia pathogenesis,” PLoS ONE, vol. 8, no. 11, 2013.

X. Wang, Y. Chen, L. Du, X. Li, X. Li, and D. Chen, “Evaluation of circulating placenta-related long noncoding RNAs as potential biomarkers for preeclampsia,” Experimental and Therapeutic Medicine, vol. 15, no. 5, pp. 4309–4317, 2018.

M. Griffith, O. L. Griffith, J. Mwenifumbo et al., “Alternative expression analysis by RNA sequencing,” Nature Methods, vol. 7, no. 10, pp. 843–847, 2010.

C. Trapnell, B. A. Williams, G. Pertea et al., “Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation,” Nature Biotechnology, vol. 28, no. 5, pp. 51–515, 2010.

S. Liu, X. Xie, H. Lei, B. Zou, and L. Xie, “Identification of key circRNAs/LncRNAs/miRNAs/miRNAs and pathways in preeclampsia using bioinformatics analysis,” Medical Science Monitor, vol. 25, pp. 1679–1693, 2019.

J. Tong, W. Zhao, H. Lv, W.-P. Li, Z.-J. Chen, and C. Zhang, “Transcriptomic profiling in human decidua of severe preeclampsia detected by RNA sequencing,” Journal of Cellular Biochemistry, vol. 119, no. 1, pp. 607–615, 2018.

M. I. Kokkinos, P. Murthi, R. Wafai, E. W. Thompson, and D. F. Newgreen, “Cadherins in the human placenta - epithelial-mesenchymal transition (EMT) and placental development,” Placenta, vol. 31, no. 9, pp. 747–755, 2010.

G. Fu, G. Ye, L. Nadeem et al., “MicroRNA-376c impairs transforming growth factor-β and nodal signaling to promote trophoblast cell proliferation and invasion,” Hypertension, vol. 61, no. 4, pp. 864–872, 2013.

X. Song, C. Rui, L. Meng et al., “Long non-coding RNA RPAIN regulates the invasion and apoptosis of trophoblast cell lines via complement protein Clq,” Oncotarget, vol. 8, no. 5, pp. 7637–7646, 2017.

C. Cao, J. Li, J. Li, L. Liu, X. Cheng, and R. Jia, “Long non-coding RNA UC.187 is upregulated in preeclampsia and modulates proliferation, apoptosis, and invasion of HTR-8/SVneo trophoblast cells,” Journal of Cellular Biochemistry, vol. 118, no. 6, pp. 1462–1470, 2017.

J. L. Li, R. Li, Y. Gao et al., “LncRNA CCAT1 promotes the progression of preeclampsia by regulating CDK4,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 5, pp. 1216–1223, 2018.

S. Jiao, S. Y. Wang, and H. Huang, “LncRNA PRNCR1 promoted the progression of eclampsia by regulating the MAPK signal pathway,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 12, pp. 3635–3642, 2018.

Y. Yan, D. Xiao, Y. Xu, and C. Wang, “Long non-coding RNA DLX6-AS1 is upregulated in preeclampsia and modulates migration and invasion of trophoblasts through the miR-376c/GADD45A axis,” Experimental Cell Research, vol. 370, no. 2, pp. 718–724, 2018.

Y. Zou, Z. Jiang, X. Yu et al., “Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8/SVneo,” PLoS ONE, vol. 8, no. 11, p. e79598, 2013.

C. B. Oudejans, A. Poutsma, O. J. Michel et al., “Noncoding RNA-regulated gain-of-function of STOX2 in Finnish pre eclamptic families,” Scientific Reports, vol. 6, no. 1, p. 32129, 2016.

M. van Dijk, H. K. Thulluru, J. Mulders et al., “HELLP babies link a novel lncRNA to the trophoblast cell cycle,” The Journal of Clinical Investigation, vol. 122, no. 11, pp. 4003–4101, 2012.

M. van Dijk, A. Visser, K. M. L. Buubeng, A. Poutsma, R. C. van der Schors, and C. B. M. Oudejans, “Mutations within the LINC-HELLP non-coding RNA differentially bind ribosomal and RNA splicing complexes and negatively affect trophoblast differentiation,” Human Molecular Genetics, vol. 24, no. 19, pp. 5475–5485, 2015.

Z. Pengjie, C. Xionghui, Z. Yueming et al., “LncRNA uc003fir promotes CCL5 expression and negatively affects proliferation and migration of trophoblast cells in preeclampsia,” Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, vol. 14, pp. 90–96, 2018.

H. Chen, X. Xu, J. Teng et al., “CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6700–6707, 2015.

X. Liu, H. Chen, W. Kong et al., “Down-regulated long non-coding RNA-ATB in preeclampsia and its effect on suppressing migration, proliferation, and tube formation of trophoblast cells,” Placenta, vol. 49, pp. 80–87, 2017.

Y. Yang, L. Xi, Y. Ma et al., “The lncRNA small nuclear RNA host gene 5 regulates trophoblast cell proliferation, invasion,
and migration via modulating miR-26a-5p/N-cadherin axis,” *Journal of Cellular Biochemistry*, vol. 120, no. 3, pp. 3173–3184, 2019.

[53] Y. Zhang, Y. Zou, W. Wang et al., “Down-regulated long non-coding RNA MEG3 and its effect on promoting apoptosis and suppressing migration of trophoblast cells,” *Journal of Cellular Biochemistry*, vol. 116, no. 4, pp. 542–550, 2015.

[54] Y. Xu, Z. Ge, E. Zhang et al., “The lncRNA TUG1 modulates proliferation in trophoblast cells via epigenetic suppression of RND3,” *Cell Death & Disease*, vol. 8, no. 10, p. e3104, 2017.

[55] Y. Xu, D. Wu, J. Liu et al., “Downregulated lncRNA HOXA11-AS affects trophoblast cell proliferation and migration by regulating RND3 and HOXA7 expression in PE,” *Molecular Therapy - Nucleic Acids*, vol. 12, pp. 195–206, 2018.

[56] W.-L. Gao, M. Liu, Y. Yang et al., “The imprinted H19 gene regulates human placental trophoblast cell proliferation via encoding miR-675 that targets nodal modulator 1 (NOMO1),” *RNA Biology*, vol. 9, no. 7, pp. 1002–1010, 2012.

[57] Z. M. Zhao and J. Jiang, “Lowly expressed EGFR-AS1 promotes the progression of preeclampsia by inhibiting the EGFR-JAK/STAT signaling pathway,” *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 19, pp. 6190–6197, 2018.

[58] D. Wu, Y. Xu, Y. Zou et al., “Long non-coding RNA 00473 is involved in preeclampsia by LSD1 binding-regulated TFPI2 transcription in trophoblast cells,” *Molecular Therapy - Nucleic Acids*, vol. 12, pp. 381–392, 2018.

[59] Y. Xu, Y. Lian, Y. Zhang et al., “The long non-coding RNA PVT1 represses ANGPTL4 transcription through binding with EZH2 in trophoblast cell,” *Journal of Cellular and Molecular Medicine*, vol. 22, no. 2, pp. 1272–1282, 2018.

[60] Y. Zou, Q. Li, Y. Xu et al., “Promotion of trophoblast invasion by lncRNA MVH through inducing Jun-B,” *Journal of Cellular and Molecular Medicine*, vol. 22, no. 2, pp. 1214–1223, 2018.

[61] P. Hsu, B. Santner-Nanan, J. E. Dahlstrom et al., “Altered decidual DC-SIGN+ antigen-presenting cells and impaired regulatory T-cell induction in preeclampsia,” *The American Journal of Pathology*, vol. 181, no. 6, pp. 2149–2160, 2012.

[62] P. Wang, Y. Xue, Y. Han et al., “The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation,” *Science*, vol. 344, no. 6181, pp. 310–313, 2014.

[63] W. Zhang, Y. Zhou, and Y. Ding, “Lnc-DC mediates the overmaturation of decidual dendritic cells and induces the increase in Th1 cells in preeclampsia,” *American Journal of Reproductive Immunology*, vol. 77, no. 6, p. e12647, 2017.

[64] X. Li, Y. Song, F. Liu et al., “Long non-coding RNA MALAT1 promotes proliferation, angiogenesis, and immnosuppressive properties of mesenchymal stem cells by inducing VEGF and IDO,” *Journal of Cellular Biochemistry*, vol. 118, no. 9, pp. 2780–2791, 2017.

[65] T. R. Mercer, M. E. Dinger, and J. S. Mattick, “Long non-coding RNAs: insights into functions,” *Nature Reviews Genetics*, vol. 10, no. 3, pp. 155–159, 2009.

[66] W.-L. Gao, D. Li, Z.-X. Xiao et al., “Detection of global DNA methylation and paternally imprinted H19 gene methylation in preeclamptic placentas,” *Hypertension Research*, vol. 34, no. 5, pp. 655–661, 2011.

[67] M. Harati-Sadegh, L. Kohan, B. Teimoori, and S. Salimi, “The long non-coding RNA H19 rs217727 polymorphism is associated with PE susceptibility,” *Journal of Cellular Biochemistry*, vol. 119, no. 7, pp. 5473–5480, 2018.